NCT02752048 is a Phase 2 clinical trial of TAS-205 in Duchenne Muscular Dystrophy, sponsored by Taiho Pharmaceutical Co., Ltd..

Who is sponsoring NCT02752048?

NCT02752048 is sponsored by Taiho Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02752048?

Interventions in NCT02752048: TAS-205, Placebo.

What condition does NCT02752048 study?

NCT02752048 studies Duchenne Muscular Dystrophy.

Is NCT02752048 still recruiting?

NCT02752048 is currently completed. Last updated 8 April 2020.

Are results published for NCT02752048?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-08 · How we verify

NCT02752048

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy

Completed Phase 2 Results posted Last updated 8 April 2020

What this trial tests

Phase 2 trial testing TAS-205 in Duchenne Muscular Dystrophy in 36 participants. Completed in 17 October 2017.

Timeline

1 May 2016

Primary endpoint
15 May 2017

17 October 2017

Quick facts

Lead sponsor	Taiho Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	1 May 2016
Primary completion	15 May 2017
Estimated completion	17 October 2017
Sites	11 locations across Japan

Drugs / interventions tested

TAS-205 — full drug profile →
Placebo

Conditions studied

Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →

Sponsor

Taiho Pharmaceutical Co., Ltd. — full company profile →

Who can join

5 and older, male only, with Duchenne Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean Change From Baseline to 24 Weeks in the 6-minute Walk Distance (6MWD)
Time frame: baseline, 24 weeks
The distance the subject can walk as fast as possible in 6 minutes will be evaluated.

Sponsor's own description

The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.
Łoboda A, Dulak J. · · 2020 · cited 57× · PMID 32691346 · DOI 10.1007/s43440-020-00134-x
Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.
Komaki H, Maegaki Y, Matsumura T, Shiraishi K, et al · · 2020 · cited 22× · PMID 31957953 · DOI 10.1002/acn3.50978
A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.
Takeshita E, Komaki H, Shimizu-Motohashi Y, Ishiyama A, et al · · 2018 · cited 20× · PMID 30480028 · DOI 10.1002/acn3.651
Targeted genetic therapies for inherited disorders that affect both cardiac and skeletal muscle.
Psaras Y, Toepfer CN. · · 2024 · cited 3× · PMID 38095849 · DOI 10.1113/ep090436
Urinary prostaglandin D<sub>2</sub> and E<sub>2</sub> metabolites are elevated with disease severity in patients with Fukuyama congenital muscular dystrophy.
Ishigaki K, Takeuchi A, Taniguchi-Ikeda M, Sato T, et al · · 2025 · cited 1× · PMID 40011677 · DOI 10.1038/s41598-025-91539-2

Verify or expand the search:

Other recruiting trials for Duchenne Muscular Dystrophy

Currently open trials in the same condition.

NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
NCT06817382 — A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Ma · Phase 1 · recruiting
NCT06402942 — Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy · NA · recruiting
NCT06450639 — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) · Phase 2 · active not recruiting
NCT06692426 — Trial of Cell Based Therapy for DMD · Phase 1 · recruiting

Other Taiho Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05691660 — A Study of TAS3731 in Healthy Adults · Phase 1 · completed
NCT05621447 — A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects · Phase 1 · completed
NCT05335499 — A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria · Phase 2 · completed
NCT04825431 — Mass Balance Study of [14C] TAS-205 in Healthy Volunteers · Phase 1 · completed
NCT04512053 — A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02752048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiho Pharmaceutical Co., Ltd.
Last refreshed: 8 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02752048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing